{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:56:02Z","timestamp":1791327362273,"version":"4.3.1"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2106,7,5]]},"DOI":"10.18632\/oncotarget.9621","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T15:34:42Z","timestamp":1464276882000},"page":"41857-41869","source":"Crossref","is-referenced-by-count":23,"title":["Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma"],"prefix":"10.18632","volume":"7","author":[{"given":"Xiaoen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Solban","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Callea","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Alsop","sequence":"additional","affiliation":[{"name":"Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Pearsall","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[{"name":"Departments of Oncology and Medicine, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Mier","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Alimzhanov","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kumar","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Bhasin","sequence":"additional","affiliation":[{"name":"Division of Interdisciplinary Medicine & Biotechnology, and Genomics, Proteomics, Bioinformatics and Systems Biology Center, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal S.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Gore","year":"2009","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Solska","year":"2009","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Castellano","year":"2011","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"McCann","year":"2010","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1158\/1535-7163.MCT-10-0477","article-title":"Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling","volume":"9","author":"Mier","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"6","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2009-07-235655","article-title":"ALK1 signaling regulates early postnatal lymphatic vessel development","volume":"115","author":"Yan","year":"2010","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1182\/blood-2012-01-407593","article-title":"BMP9 and BMP10 are critical for postnatal retinal vascular remodeling","volume":"119","author":"Bailly","year":"2012","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-13-2788","article-title":"Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?","volume":"20","author":"Atkins","year":"2014","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"Bailly","year":"2007","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/labinvest.3700376","article-title":"Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development","volume":"86","author":"Oh","year":"2006","journal-title":"Lab Invest"},{"key":"11","doi-asserted-by":"crossref","first-page":"30034","DOI":"10.1074\/jbc.M111.260133","article-title":"Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth","volume":"286","author":"Grinberg","year":"2011","journal-title":"J Biol Chem"},{"key":"12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1535-7163.MCT-09-0650","article-title":"ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth","volume":"9","author":"Kumar","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"13","doi-asserted-by":"crossref","first-page":"e50920","DOI":"10.1371\/journal.pone.0050920","article-title":"Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies","volume":"7","author":"Ruefli-Brasse","year":"2012","journal-title":"PLoS One"},{"key":"14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng0696-189","article-title":"Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2","volume":"13","author":"Attisano","year":"1996","journal-title":"Nat Genet"},{"key":"15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng1294-345","article-title":"Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1","volume":"8","author":"Murrell","year":"1994","journal-title":"Nat Genet"},{"key":"16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI8088","article-title":"A murine model of hereditary hemorrhagic telangiectasia","volume":"104","author":"Letarte","year":"1999","journal-title":"J Clin Invest"},{"key":"17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/hmg\/ddg050","article-title":"A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2","volume":"12","author":"Marchuk","year":"2003","journal-title":"Hum Mol Genet"},{"key":"18","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1182\/blood.V100.13.4495","article-title":"Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis","volume":"100","author":"Bailly","year":"2002","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1084\/jem.20091309","article-title":"Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis","volume":"207","author":"Pietras","year":"2010","journal-title":"J Exp Med"},{"key":"20","first-page":"3487","article-title":"Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia","volume":"119","author":"Oh","year":"2009","journal-title":"J Clin Invest"},{"key":"21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0022-3565(25)12892-9","article-title":"Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors","volume":"277","author":"Koch","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2013.06.004","article-title":"A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis","volume":"24","author":"Lopez-Berestein","year":"2013","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","article-title":"Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies","volume":"71","author":"Erbersdobler","year":"2011","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jcp.20311","article-title":"Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex","volume":"204","author":"Bernabeu","year":"2005","journal-title":"J Cell Physiol"},{"key":"25","doi-asserted-by":"crossref","first-page":"25110","DOI":"10.1074\/jbc.M601288200","article-title":"Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors","volume":"281","author":"Vary","year":"2006","journal-title":"J Biol Chem"},{"key":"26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2012-12-472142","article-title":"Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation","volume":"122","author":"Vittet","year":"2013","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.devcel.2012.02.005","article-title":"ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway","volume":"22","author":"Eichmann","year":"2012","journal-title":"Dev Cell"},{"key":"28","doi-asserted-by":"crossref","first-page":"e112371","DOI":"10.1371\/journal.pone.0112371","article-title":"Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts","volume":"9","author":"Pili","year":"2014","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-12-0098","article-title":"A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer","volume":"18","author":"Gordon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/156720111793663570","article-title":"Endoglin-targeted cancer therapy","volume":"8","author":"Haruta","year":"2011","journal-title":"Curr Drug Deliv"},{"key":"31","doi-asserted-by":"crossref","first-page":"18551","DOI":"10.1074\/jbc.M111.338103","article-title":"Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting","volume":"287","author":"ten Dijke","year":"2012","journal-title":"J Biol Chem"},{"key":"32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-13-1840","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer","volume":"20","author":"Attie","year":"2014","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1148\/radiol.2521081059","article-title":"Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?","volume":"251","author":"Goldberg","year":"2009","journal-title":"Radiology"},{"key":"34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bjc.2012.591","article-title":"Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts","volume":"108","author":"Bhatt","year":"2013","journal-title":"Br J Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/00004647-199611000-00019","article-title":"Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow","volume":"16","author":"Detre","year":"1996","journal-title":"J Cereb Blood Flow Metab"},{"key":"36","doi-asserted-by":"crossref","first-page":"e19099","DOI":"10.1371\/journal.pone.0019099","article-title":"Optimization of MicroCT Imaging and Blood Vessel Diameter Quantitation of Preclinical Specimen Vasculature with Radiopaque Polymer Injection Medium","volume":"6","author":"Reddy","year":"2011","journal-title":"PLoS ONE"},{"key":"37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1479-5876-9-220","article-title":"High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma","volume":"9","author":"Bhatt","year":"2011","journal-title":"J Transl Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","article-title":"TopHat: discovering splice junctions with RNA-Seq","volume":"25","author":"Salzberg","year":"2009","journal-title":"Bioinformatics"},{"key":"39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Smyth","year":"2010","journal-title":"Bioinformatics"},{"key":"40","first-page":"11","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Hochberg","year":"1995","journal-title":"Journal of the Royal Statistical Society: Series B"},{"key":"41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/bioinformatics\/17.9.763","article-title":"Principal component analysis for clustering gene expression data","volume":"17","author":"Ruzzo","year":"2001","journal-title":"Bioinformatics"},{"key":"42","doi-asserted-by":"crossref","first-page":"D6","DOI":"10.1093\/nar\/gku1130","article-title":"Database resources of the National Center for Biotechnology Information","volume":"43","author":"NCBI Resource Coordinators","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in Ingenuity Pathway Analysis","volume":"30","author":"Tugendreich","year":"2014","journal-title":"Bioinformatics"},{"key":"44","first-page":"7","article-title":"On the Interpretation of xfrom Contingency Tables, and the Calculation of P","volume":"85","author":"Fisher","year":"1992","journal-title":"Journal of the Royal Statistical Society"},{"key":"45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2105-13-134","article-title":"Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction","volume":"13","author":"Madden","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yexmp.2005.03.004","article-title":"Quantitative multi-gene transcriptional profiling using real-time PCR with a master template","volume":"79","author":"Smith","year":"2005","journal-title":"Exp Mol Pathol"},{"key":"47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)64154-5","article-title":"Molecular profiling of angiogenesis markers","volume":"161","author":"Senger","year":"2002","journal-title":"Am J Pathol"},{"key":"48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"},{"key":"49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-61779-361-5_19","article-title":"Analyzing biological data using R: methods for graphs and networks","volume":"804","author":"Gentleman","year":"2012","journal-title":"Methods Mol Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:39:37Z","timestamp":1748979577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":49,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2106,7,5]]}},"alternative-id":["9621","27248821"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9621","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}